Cara Therapeutics Inc., of Shelton, Conn., has commenced an underwritten public offering of shares of its common stock of up to $65 million, granting the underwriters a 30-day option to purchase an additional 15 percent of the number of shares sold on the same terms and conditions. Stifel and Piper Jaffray & Co. are acting as joint book-running managers for the proposed offering.